Cite
Rosenson RS, Jacobson TA, Preiss D, et al. Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovasc Drugs Ther. 2016;30(5):537doi: 10.1007/s10557-016-6684-z.
Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, S. C., Dent, R., Bridges, I., & Miller, M. (2016). Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovascular drugs and therapy, 30(5), 537. https://doi.org/10.1007/s10557-016-6684-z
Rosenson, Robert S, et al. "Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia." Cardiovascular drugs and therapy vol. 30,5 (2016): 537. doi: https://doi.org/10.1007/s10557-016-6684-z
Rosenson RS, Jacobson TA, Preiss D, Djedjos SC, Dent R, Bridges I, Miller M. Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovasc Drugs Ther. 2016 Oct;30(5):537. doi: 10.1007/s10557-016-6684-z. PMID: 27497929; PMCID: PMC6828239.
Copy
Download .nbib